関連文献

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed

Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.

Heart Vessels. 30(3): 296-303, 2015.PubMed

Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.

Am J Physiol Renal Physiol. 308(2): F114-121, 2014.PubMed

Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

AIDS Res Hum Retroviruses. 30(4): 363-369, 2014.PubMed

Remote Ischemic Pre-Conditioning Alleviates ContrastInduced Acute Kidney Injury in Patients With Moderate Chronic Kidney Disease.

Circulation Journal. 77(12): 3037-3044, 2013.PubMed

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.

Eur J Clin Invest. 42(5): 557-563, 2012.PubMed

Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.

Am J Pathol. 178(3): 1021-1032, 2011.PubMed

Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.

Am J Pathol. 174(6): 2096-2106, 2009.PubMed

Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.

Am J Pathol. 174(4): 1154-1159, 2009.PubMed

Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

Nephron Exp Nephrol. 108(1): e19-26, 2008.PubMed